Recombinant Human IL-17C (C-6His)

Description

EnkiLife provides the Recombinant Human IL-17C (C-6His) protein,aslo know as CX2,Cytokine CX2,IL17C,IL-17C,IL-17CMGC126884,interleukin 17C,interleukin-17C, which features high purity, high activity, and high stability. It can be applied in scientific research, biopharmaceuticals, and other fields.Purity:Greater than 95% as determined by reducing SDS-PAGE;Endotoxin Level:<1 EU/µg as determined by LAL test.;Construction:Recombinant Human Interleukin-17C is produced by our Mammalian expression system and the target gene encoding His19-Val197 is expressed with a 6His tag at the C-terminus.Accession:Q9P0M4. Expression Host:Human Cells.Species:Human.Predicted Molecular Mass:20.6 KDa. Background:Interleukin 17C (IL 17C) is a 15 20 kDa glycosylated cytokine that plays an important role in mucosal immunity and chronic inflammation. IL 17C binds to IL 17 RE with high affinity and to IL 17 RA with low affinity. These two receptor chains can associate into a heterodimeric receptor for IL 17C. IL 17C expression is induced by inflammatory stimulation in colon and airway epithelial cells, keratinocytes, CD4+ T cells, macrophages, and dendritic cells. It is up regulated in various chronic inflammatory diseases including psoriasis, cystic fibrosis, and chronic obstructive pulmonary disease (COPD). IL 17 RE is reciprocally down regulated in psoriatic lesions. The interaction of IL 17C with IL 17 RE promotes mucosal immunity through the induction of anti bacterial peptides and pro inflammatory cytokines and chemokines. IL 17C action supports the integrity of the colon epithelium following infection induced damage but also contributes to psoriatic skin thickening and the progression of arthritis. IL 17C is additionally up regulated in Th17 cell dependent autoimmunity. In this setting, it exacerbates disease severity by inducing Th17 cell production of IL 17A, IL 17F, IL 22, CCR6, and CCL20.